Theunissen et al reported a model for predicting hearing loss following chemoradiotherapy including cisplatin. This can help to identify a patient who may require close monitoring of hearing after therapy. The authors are from multiple institutions in The Netherlands.
Patient selection: recipient of chemoradiotherapy including cisplatin for head and neck cancer
Audiometry testing: pure-tone audiometry (PTA)
Parameters:
(1) total cisplatin dose in milligrams
(2) high pretreatment PTA of 1-2-4 kHz bone conduction in decibels
(3) low pretreatment PTA of 0.5-1-2 kHz bone conduction in decibels
(4) ultrahigh pretreatment PTA of 8-10-12.5 kHz air conduction in decibels
(5) radiation dose in Gray
Parameter
Points
cisplatin dose
0.02 * (dose)
high pretreatment PTA
0.68 * (decibels)
low pretreatment PTA
0.05 * (decibels)
ultrahigh pretreatment PTA
0.68 * (decibels)
radiation dose
0.21 * (radiation dose)
post-treatment PTA at 1-2-4 Hz =
= SUM(points for all 5 parameters) - 5.56
To read more or access our algorithms and calculators, please log in or register.
